Methylstenbolone
Designer prohormone/AAS briefly sold legally in the US (2010–2012) before DEA scheduling. 2-methyl, 17α-methyl DHT derivative. Produces rapid strength and size gains. Very hepatotoxic with notable cardiovascular impact. Limited human pharmacokinetic data available.
Mechanism of Action
DHT-derived — no aromatization. 2-methyl modification increases anabolic potency similarly to methasterone. 17α-methylation provides oral activity. High AR binding affinity documented in vitro. No 5α-reduction pathway. SHBG binding may contribute to libido-altering effects.
Typical Dosing
⚠ Warning Flags
- •Very limited human safety data
- •Hepatotoxic — liver enzymes elevate rapidly
- •DEA Schedule III in the US
Effect Profile
Side Effect Profile
Research Studies
Identification and detection of designer steroids in supplements: methylstenbolone
Geyer H, et al. · 2011
Methylstenbolone was identified in commercially sold prohormone products; doping control urine analyses confirmed its metabolites and established detection windows of 3–5 days post-cessation.